Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBD-TT
- Development stage
- Unknown
- Lead developer
- Finlay Vaccine Institute
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
RBD-TT (also known as Soberana 02 or PastoCovac) is a COVID-19 conjugate vaccine developed by the Finlay Vaccine Institute of Cuba in collaboration with the Pasteur Institute of Iran and the Center for Molecular Immunology. The vaccine consists of the recombinant receptor-binding domain (RBD) of the SARS-CoV-2 spike glycoprotein chemically conjugated to a tetanus toxoid (TT) carrier protein, adsorbed on aluminum hydroxide gel. This conjugation enhances the immunogenicity of the RBD antigen, promoting a robust neutralizing antibody response and long-term B-cell memory. RBD-TT has been approved for emergency use in Cuba, Iran, Venezuela, and Nicaragua, and has been evaluated in clinical trials for both adult and pediatric populations, as well as in immunocompromised patients such as hematopoietic stem cell transplant recipients.
- Brand names
- PastoCovacPasteurcovacSoberana 02Soberana02Soberana-02Soberana II
- Other names
- FINLAY-FR-2FINLAY-FR2FINLAY-FR 2Pasto CovacRBD-TT conjugateSoberana 2Soberana2Soberana-2Soberana-02Soberana02Soberana 02recombinant receptor-binding domain-tetanus toxoid conjugate
02
Targets
ACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on RBD-TT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBD-TT.